AtriCure's (ATRC) "Sell (D-)" Rating Reiterated at Weiss Ratings

Key Points

• AtriCure's stock has been rated a "Sell (D-)" by Weiss Ratings, while other analysts have issued more favorable ratings, including a "Buy" from Wall Street Zen.
• The company's recent quarterly earnings report showed a revenue increase of 17.1% year-over-year, with an EPS of ($0.02), exceeding estimates by $0.13.
• Insider trading activity includes the sale of 17,952 shares by insiders in the last three months, with directors reducing their ownership stakes significantly.

AtriCure (NASDAQ:ATRC - Get Free Report)'s stock had its "sell (d-)" rating reissued by research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

A number of other analysts have also commented on the stock. Wall Street Zen upgraded shares of AtriCure from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Needham & Company LLC increased their price target on shares of AtriCure from $44.00 to $45.00 and gave the company a "buy" rating in a research report on Wednesday, July 30th. Finally, BTIG Research set a $54.00 price target on shares of AtriCure in a research report on Wednesday, July 30th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $50.89.

AtriCure Stock Up 2.8%

ATRC traded up $0.96 during trading hours on Wednesday, hitting $35.08. 189,258 shares of the company's stock were exchanged, compared to its average volume of 551,672. AtriCure has a 1-year low of $25.57 and a 1-year high of $43.11. The stock's 50-day moving average is $35.87 and its two-hundred day moving average is $33.49. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of -45.56 and a beta of 1.59. The company has a quick ratio of 2.83, a current ratio of 3.94 and a debt-to-equity ratio of 0.16.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The medical device company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.13. AtriCure had a negative net margin of 7.27% and a negative return on equity of 4.20%. The company had revenue of $136.14 million for the quarter, compared to analyst estimates of $130.17 million. During the same period in the prior year, the firm earned ($0.17) earnings per share. The company's revenue was up 17.1% on a year-over-year basis. AtriCure has set its FY 2025 guidance at -0.390--0.340 EPS. Sell-side analysts predict that AtriCure will post -0.6 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Sven Wehrwein sold 5,000 shares of AtriCure stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $37.00, for a total value of $185,000.00. Following the sale, the director directly owned 34,374 shares of the company's stock, valued at $1,271,838. The trade was a 12.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Justin J. Noznesky sold 3,000 shares of the business's stock in a transaction on Friday, September 12th. The stock was sold at an average price of $36.30, for a total value of $108,900.00. Following the transaction, the insider directly owned 83,964 shares in the company, valued at $3,047,893.20. This trade represents a 3.45% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 17,952 shares of company stock valued at $655,633 in the last three months. 3.50% of the stock is currently owned by company insiders.

Institutional Trading of AtriCure

Hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC raised its stake in shares of AtriCure by 9,664.9% during the 1st quarter. GAMMA Investing LLC now owns 3,613 shares of the medical device company's stock worth $112,000 after buying an additional 3,576 shares in the last quarter. Harbor Capital Advisors Inc. purchased a new position in shares of AtriCure during the 1st quarter worth approximately $916,000. Assenagon Asset Management S.A. raised its stake in shares of AtriCure by 5.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 146,096 shares of the medical device company's stock worth $4,713,000 after buying an additional 6,995 shares in the last quarter. WCM Investment Management LLC raised its stake in shares of AtriCure by 0.8% during the 1st quarter. WCM Investment Management LLC now owns 193,352 shares of the medical device company's stock worth $6,154,000 after buying an additional 1,551 shares in the last quarter. Finally, First Horizon Advisors Inc. increased its stake in AtriCure by 135.3% in the 1st quarter. First Horizon Advisors Inc. now owns 1,447 shares of the medical device company's stock valued at $47,000 after purchasing an additional 832 shares in the last quarter. 99.11% of the stock is owned by institutional investors and hedge funds.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.